🇺🇸 Coristina d in United States

25 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 25

Most-reported reactions

1. Diarrhoea — 4 reports (16%)
2. Drug Ineffective — 4 reports (16%)
3. Malaise — 3 reports (12%)
4. Accidental Exposure — 2 reports (8%)
5. Arterial Occlusive Disease — 2 reports (8%)
6. Asthenia — 2 reports (8%)
7. Blood Glucose Increased — 2 reports (8%)
8. Depression — 2 reports (8%)
9. Dizziness — 2 reports (8%)
10. Influenza — 2 reports (8%)

Source database →

Frequently asked questions

Is Coristina d approved in United States?

Coristina d does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Coristina d in United States?

Brainfarma Industria Química e Farmacêutica S/A is the originator. The local marketing authorisation holder may differ — check the official source linked above.